The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

Pulmonary Histoplasmosis

Endemic systemic mycosis caused by Histoplasma capsulatum (or H. duboisii in Africa), inhaled from soil contaminated with bird or bat droppings in endemic regions (Ohio/Mississippi River valleys, Central/South America, Africa), with clinical spectrum from asymptomatic to chronic cavitary pulmonary disease and disseminated forms in immunocompromised hosts.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Pulmonary Histoplasmosis?

Pulmonary histoplasmosis is the most common endemic systemic mycosis in North America, caused by Histoplasma capsulatum var. capsulatum (or H. capsulatum var. duboisii in Africa, predominantly cutaneous and bone disease). Histoplasma is a thermally dimorphic fungus existing as mold (mycelial form) in soil at ambient temperature and yeast form at 37°C in tissue. The fungus thrives in soil enriched with nitrogen from bird droppings (especially starlings, blackbirds, chickens) and bat guano in caves.

Endemic regions include the Ohio and Mississippi River valleys in the United States (highest endemicity), parts of Central and South America (Mexico, Brazil, Venezuela), the Caribbean, parts of Africa, India, and Southeast Asia. Outbreaks occur after disturbance of contaminated soil (cave exploration, demolition, excavation, chicken coop cleaning). Microconidia are inhaled, deposited in alveoli, and converted to yeast form, ingested by macrophages where they multiply intracellularly. Infection ranges from asymptomatic (95% with low-inoculum exposure) to severe disease.

Clinical syndromes include: (1) acute pulmonary histoplasmosis — flu-like illness with fever, chills, headache, dry cough, chest discomfort 2-3 weeks after high-inoculum exposure, with hilar/mediastinal adenopathy and patchy infiltrates; (2) chronic cavitary pulmonary histoplasmosis — in patients with structural lung disease (COPD, emphysema), mimicking tuberculosis with apical cavitary disease, weight loss, hemoptysis; (3) histoplasmoma — solitary pulmonary nodule with concentric calcification; (4) mediastinal granuloma — caseating necrosis of mediastinal nodes with potential to develop fibrosing mediastinitis (rare but devastating, with vascular and airway compression); (5) progressive disseminated histoplasmosis (PDH) — in immunocompromised hosts (HIV with CD4 less than 150, solid organ or stem cell transplant, biologic agents like TNF-alpha inhibitors, congenital immunodeficiency) with fever, weight loss, hepatosplenomegaly, pancytopenia, oral ulcers, adrenal involvement, CNS disease (10-25%); rapidly fatal without treatment. Diagnosis: urine Histoplasma antigen (highest sensitivity in PDH, over 90%), serum antigen, complement fixation and immunodiffusion serology, fungal culture (slow, weeks), histopathology with GMS or PAS staining showing intracellular yeasts in macrophages. Treatment: itraconazole 200 mg twice daily for mild-moderate disease; liposomal amphotericin B 3 mg/kg/day for severe disease, switched to itraconazole maintenance for total 12 months (PDH) or 12-24 months (chronic cavitary). HIV patients with CD4 less than 150 require lifelong secondary prophylaxis with itraconazole.

Symptoms

Asymptomatic in 95% of low-inoculum exposures
Flu-like illness with fever, chills, headache, dry cough (acute pulmonary)
Erythema nodosum or erythema multiforme
Chronic cough with hemoptysis (chronic cavitary)
Weight loss, night sweats, fatigue (chronic or disseminated)
Oral ulcers, hepatosplenomegaly, pancytopenia (PDH)
Dysphagia, superior vena cava syndrome (mediastinal fibrosis)

Risk Factors

Travel or residence in endemic regions (Ohio/Mississippi valleys, Central/South America)
Exposure to bird (starling, chicken coop) or bat droppings (caves)
HIV/AIDS with CD4 less than 150 (PDH risk)
Solid organ or hematopoietic stem cell transplantation
TNF-alpha inhibitor or other biologic immunosuppressives
Chronic structural lung disease (COPD — chronic cavitary form)
Excavation, demolition, or cave exploration in endemic areas

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Flu-like illness after spelunking or chicken coop cleaning in endemic area
  • Chronic cavitary lung lesion mimicking tuberculosis in COPD patient
  • Solitary pulmonary nodule in patient from endemic region
  • Persistent cough or weight loss with mediastinal adenopathy
  • PDH symptoms in HIV or transplant patient (fever, hepatosplenomegaly)
  • Oral ulcers in immunocompromised patient with constitutional symptoms
  • Suspected fibrosing mediastinitis with vascular or airway compression

Treatment Methods

01
Asymptomatic or mild self-limited acute infection — observation
02
Itraconazole 200 mg twice daily for mild-moderate symptomatic disease
03
Liposomal amphotericin B 3 mg/kg/day for severe pulmonary or disseminated disease (induction 1-2 weeks)
04
Switch to itraconazole maintenance for total 12 months (PDH) or 12-24 months (chronic cavitary)
05
Lifelong secondary prophylaxis (itraconazole 200 mg/day) in HIV with CD4 less than 150 unless immune reconstitution
06
Therapeutic drug monitoring of itraconazole levels (target 1-2 μg/mL)
07
Surgical resection for histoplasmoma (rarely needed) or fibrosing mediastinitis (not effective)

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.